Top-Rated StocksTop-RatedNASDAQ:IMVT Immunovant (IMVT) Stock Price, News & Analysis $28.45 -0.06 (-0.21%) (As of 10/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Immunovant Stock (NASDAQ:IMVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunovant alerts:Sign Up Key Stats Today's Range$28.05▼$28.7850-Day Range$26.71▼$34.0352-Week Range$24.67▼$45.58Volume912,378 shsAverage Volume1.14 million shsMarket Capitalization$4.16 billionP/E RatioN/ADividend YieldN/APrice Target$49.09Consensus RatingBuy Company OverviewImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Read More… Next Week Elon Could Trigger a Boom in this Sub-$3 Stock (Ad)Next week, you’ll have a chance to get in on the ground floor of what could be Elon’s next big thing. You see, he’s set to reveal his new AI product that I believe will shock the world… Click here to see the details and save your seat. Immunovant Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks36th Percentile Overall ScoreIMVT MarketRank™: Immunovant scored higher than 36% of companies evaluated by MarketBeat, and ranked 826th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingImmunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunovant has only been the subject of 4 research reports in the past 90 days.Read more about Immunovant's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($2.43) to ($2.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -14.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -14.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 6.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunovant's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.09% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Immunovant has recently increased by 0.56%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted20.09% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Immunovant has recently increased by 0.56%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.88 News SentimentImmunovant has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Immunovant this week, compared to 5 articles on an average week.Search Interest16 people have searched for IMVT on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $904,638.00 in company stock.Percentage Held by InsidersOnly 5.90% of the stock of Immunovant is held by insiders.Percentage Held by Institutions47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunovant's insider trading history. Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Stock News HeadlinesBuy Rating for Immunovant: A New Hope in Graves’ Disease TreatmentOctober 1 at 4:02 PM | markets.businessinsider.comIs Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?October 1 at 4:02 PM | finance.yahoo.com$20 = Ounce of Gold?I've discovered a way to get exposure to MORE than an ounce of gold... for under $20. It's not bullion. It's not ETFs. And it's certainly not crypto.October 2, 2024 | Monument Traders Alliance (Ad)Immunovant's (IMVT) "Buy" Rating Reaffirmed at HC WainwrightOctober 1 at 4:21 AM | americanbankingnews.comImmunovant (NASDAQ:IMVT) Stock Price Up 2.7%September 27, 2024 | americanbankingnews.comBuy Rating Backed by Promising Batoclimab Results for Graves’ Disease TreatmentSeptember 25, 2024 | markets.businessinsider.comBuy Recommendation: Immunovant’s Novel Therapy Addresses Unmet Needs in Graves’ Disease TreatmentSeptember 25, 2024 | markets.businessinsider.comAcelyrin: Straight Move To Phase 3 TED Studies Makes It Must WatchSeptember 20, 2024 | seekingalpha.comSee More Headlines IMVT Stock Analysis - Frequently Asked Questions How have IMVT shares performed this year? Immunovant's stock was trading at $42.13 on January 1st, 2024. Since then, IMVT shares have decreased by 32.5% and is now trading at $28.45. View the best growth stocks for 2024 here. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) announced its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.07. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV) and Alibaba Group (BABA). Company Calendar Last Earnings8/06/2024Today10/01/2024Next Earnings (Estimated)11/14/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMVT CUSIPN/A CIK1764013 Webwww.immunovant.com Phone917-580-3099FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$49.09 High Stock Price Target$57.00 Low Stock Price Target$41.00 Potential Upside/Downside+72.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-259,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.07% Return on Assets-48.25% Debt Debt-to-Equity RatioN/A Current Ratio13.09 Quick Ratio13.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.25 per share Price / Book6.69Miscellaneous Outstanding Shares146,180,000Free Float137,555,000Market Cap$4.16 billion OptionableOptionable Beta0.67 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:IMVT) was last updated on 10/2/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredThey laughed when he picked Nvidia in 2016…Everyone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredFor Elon, I fear the worst is yet to come…Early last year I predicted that there would be a war on Elon Musk. This hateful rhetoric has led to two s...Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.